SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Organovo Holdings, Inc. (ONVO)

ONVO RSS Feed
Add ONVO Price Alert      Hide Sticky   Hide Intro
Moderator: Dadx4
Search This Board: 
Last Post: 8/19/2017 9:43:43 AM - Followers: 316 - Board type: Free - Posts Today: 1

WELCOME TO THE ORGANOVO BOARD


 
     Organovo is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications.
The company's NovoGen three-dimensional bioprinting technology is a platform that works across all tissue and cell types.
Organovo's NovoGen MMX Bioprinter was selected as one of the "Best Inventions of 2010" by TIME Magazine.
Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic drug discovery and development.
Organovo's bioprinting technology can also be developed to create surgical tissues direct therapy.
Organovo leads the way in solving complex medical research problems and building the future of medicine.

COMPANY PROFILE via YouTube
http://www.youtube.com/watch?feature=player_embedded&v=-A-uH15bQZw

 
ONVO Security Details Share Structure

Shares Outstanding 77,816,787 a/o Mar 16, 2014
Float 50,000,000 a/0 May24,2014
Authorized Shares 150,000,000 a/o May24, 2014


IR and Media Contacts:
Investor Relations Contact: ir@organovo.com
Media Contact: media@organovo.com

Mailing Address:
Organovo, Inc.
6275 Nancy Ridge Drive, Suite 110
San Diego, CA 92121
Phone: 1-858-550-9994


For all the latest company information, details, news, please visit http://www.organovo.com

 
Organovo's Scientific Founder and Chief Scientific Officer, Dr. Gabor Forgacs
is the Executive and Scientific Director of the Shipley Center for Innovation at Clarkson University and the George H. Vineyard Professor of Biological Physics at the University of Missouri.
He developed Organovo's breakthrough organ printing technology while leading a team of top regenerative medicine scientists from multiple universities, with the backing of a $5MM National Science Foundation Grant.
Professor Forgacs is the author of more than 150 peer reviewed journal articles and the textbook Biological Physics of the Developing Embryo, (with Stuart Newman), published by Cambridge University Press.
He holds a PhD in theoretical physics from the Roland Eotvos University, Budapest Hungary. He moved to the United States in the 1980's from the Institute of Physics of the French Atomic Energy Agency in Saclay to accept a professorship at Clarkson University. 
University of Missouri researcher doing groundbreaking work in regenerative medicine. Here is a video:

Science

Organovo strives to advance regenerative medicine to new heights, by enabling bioprinting tissues and 3-D cellular constructs that were not possible before.
The novel and flexible capabilities of the bioprinting technology allow researchers to generate data faster and more efficiently, thus leading to cutting edge scientific findings, publications, and grants.

Organovo's 3-D NovoGen bioprinting technology allows for the placement of cells in any pattern desired.
First, small building blocks of any shape are created from the desired cell type.
Second, these pre-formed cell aggregates are loaded into a print cartridge that is then attached to the bio-printer.
The bioprinter deposits the cell aggregates one layer at a time, creating multiple stacked 2-D patterns.
A non-invasive gel is placed next to the cell aggregates to hold the desired 3-D shape as each layer is placed in 2-D.

After printing, the cell aggregates retain enough cellular mobility for them to flow into one another, creating a fused tissue construct.
The principles of developmental biology, including cellular self-assembly, allow the final construct to mature into the desired shape and properties.

 

World class support for NovoGen MMX

The NovoGen MMX Bioprinter™ is supported by our scientific and engineering team.
Every customer receives bioprinter training and access to Organovo's scaffold-free proprietary bioprinting process, which includes cell preparation to tissue maturation.
Additional consultation and application support are available upon request. Organovo's success comes from enabling our customers' success.  

 

NovoGen MMX Bioprinter

    The NovoGen MMX Bioprinter™ is a novel hardware and software platform at the forefront of bioprinting research and development. The NovoGen MMX™ was developed to meet challenges in biological research.
The platform takes primary or other human cells and shapes them into 3D tissue, with tremendous cellular viability and biology that is superior to even an animal model.
The platform is being used by Organovo's Pharma partners today to enable cutting edge research into drug discovery.

By allowing creation of three dimensional biological structures, Organovo creates functional human tissue that is superior to current disease models.
By enabling printing of tissue in a laboratory environment, investigations on the constructs can be integrated into your current analysis methods.

http://www.invetech.com.au/portfolio/life-sciences/3d-bioprinter-world-first-print-human-tissue/
http://techli.com/2012/07/organovo-bioprinting/#.
https://www.youtube.com/watch?v=1O3c3pUg0L8 (at 28 sec into the video is a full frontal view of the ONVO NovaGen MMX Bioprinter)

ONVO
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ONVO News: Statement of Changes in Beneficial Ownership (4) 08/17/2017 04:54:01 PM
ONVO News: Statement of Changes in Beneficial Ownership (4) 08/17/2017 04:52:40 PM
ONVO News: Statement of Changes in Beneficial Ownership (4) 08/17/2017 04:51:18 PM
ONVO News: Statement of Changes in Beneficial Ownership (4) 08/17/2017 04:50:49 PM
ONVO News: Statement of Changes in Beneficial Ownership (4) 08/17/2017 04:49:51 PM
PostSubject
#9959  Sticky Note Organovo Collaborates With University of Virginia to Develop Dadx4 05/01/17 08:29:13 AM
#10038   His track record seems smooth if I am TheBigWhale 08/19/17 09:43:43 AM
#10037   Yeah I didn't. LOL rayank 08/18/17 11:00:28 AM
#10036   Why would you punish yourself? RallyTheMarket 08/18/17 10:46:06 AM
#10035   Will be adding at 1.75 Oil Man 2 08/18/17 05:49:55 AM
#10034   Any upcoming catalysts? Might get back in? rayank 08/17/17 04:43:12 PM
#10033   Nonsense. This is a public company. Doesn't make RallyTheMarket 08/14/17 02:37:33 PM
#10032   Oh, I think they are not telling us morley480 08/12/17 10:49:02 AM
#10031   Interesting... Look up Dr. Doris Taylor at the CIMA7 08/12/17 04:44:49 AM
#10030   Oh yes. You are not the only morley480 08/04/17 02:02:05 PM
#10029   The potential of ONVO is in the therapeutic RandolRocketman 08/04/17 01:27:52 PM
#10028   That seems to me a sensible analysis. morley480 08/04/17 12:18:53 PM
#10027   This reminds me a lot of MAKO Surgical pupuguru 08/04/17 11:43:33 AM
#10026   Hey I can't argue with that. I respect adeezl 08/04/17 10:58:31 AM
#10025   Thanks Pupu, rongreen 08/03/17 08:48:29 PM
#10024   Why we are where we are....my $.02.. pupuguru 08/03/17 04:48:21 PM
#10023   just a random guess but thanks Dad for Windbag1014 08/02/17 10:42:38 PM
#10022   The upside potential is tremendous. phytokaiser1 08/02/17 08:05:52 AM
#10021   hm, well maybe, but I've been fortunate to RandolRocketman 08/01/17 09:41:33 PM
#10020   It seems like a regular pump and dump adeezl 08/01/17 06:36:23 PM
#10019   Organovo and UC San Diego Receive $1.7 Million Dadx4 07/31/17 10:05:56 AM
#10018   And some cash rolling. Nice :) RandolRocketman 07/31/17 08:35:25 AM
#10017   https://www.theguardian.com/technology/2017/jul/30/will-3d-printing-solve-the-or RandolRocketman 07/31/17 12:33:58 AM
#10016   I got out at $2.80s but sorry to rayank 07/20/17 01:11:51 PM
#10015   Elton John would know exactly what to say RallyTheMarket 07/17/17 02:00:52 PM
#10014   This type of work between Organovo, Yale, and morley480 07/14/17 11:12:04 AM
#10013   Using Three-Dimensional Bioprinting To Create Vascular Grafts: A rongreen 07/14/17 10:15:09 AM
#10012   Taylor Crouch, from the recent earnings call: rongreen 07/11/17 04:51:03 PM
#10011   Seems to me like this agreement is for phytokaiser1 07/11/17 10:38:16 AM
#10010   Inmed partnered with Altera for skin tissues for bigideaportugal 07/10/17 09:48:38 PM
#10009   There is so much creativity in the world, WHP03 07/09/17 10:19:30 PM
#10008   Interesting.. https://www.technologyreview.com/s/608141/organoids-proposed-to-s stuinvest 07/08/17 09:45:22 PM
#10007   whispers, zoom zoom. RandolRocketman 06/22/17 06:44:09 PM
#10006   ...only time will tell if they hit their WHP03 06/17/17 09:58:34 PM
#10005   You know what kills me about ONVO, if RandolRocketman 06/17/17 06:35:15 PM
#10004   Like someone else mentioned here, we've been hearing RandolRocketman 06/17/17 06:25:07 PM
#10003   Some of us longs have closed positions in RandolRocketman 06/17/17 06:21:21 PM
#10002   Exactly phytokaiser1 06/12/17 08:37:04 AM
#10001   5 yrs is a very long time, and WHP03 06/11/17 10:13:41 PM
#10000   3d Bioprinted human organs with matching DNA for RandolRocketman 06/10/17 06:00:18 PM
#9999   This news might be a good thing if CIMA7 06/10/17 01:31:11 AM
#9998   Wasn't much to like in the filing or WHP03 06/09/17 08:47:02 PM
#9997   Appears that the 10-k was not very well Alvie 06/09/17 10:06:35 AM
#9996   Full-Year Fiscal 2017 Organovo Business Highlights RandolRocketman 06/07/17 04:23:46 PM
#9995   BY Fly On The Wall RandolRocketman 06/07/17 03:36:28 PM
#9994   Any predictions on the upcoming Q4 earnings report? RandolRocketman 06/07/17 03:04:50 PM
#9991   Odd turn of events in Organovo's suit against rongreen 06/06/17 04:38:30 PM
#9990   Nice dip and rip, fully reloaded here we jjh573 06/05/17 01:56:12 PM
#9989   Organovo to Present at Jefferies Healthcare Conference RandolRocketman 06/05/17 09:46:26 AM
#9988   nice dshade 06/02/17 10:20:56 AM
#9987   Market Capitalization $311.14M RandolRocketman 05/31/17 09:57:06 AM
PostSubject